Jacques D Du Toit

Dr. Jacques D Du Toit


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KSKaiyuan Sun
Kaiyuan Sun
JBJinal N. Bhiman
Jinal N. Bhiman
STStefano Tempia
Stefano Tempia
JKJackie Kleynhans
Jackie Kleynhans
VMVimbai Sharon Madzorera
Vimbai Sharon Madzorera
FWFloidy Wafawanaka
Floidy Wafawanaka

16 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKaiyuan Sun
Kaiyuan Sun
STStefano Tempia
Stefano Tempia
JKJackie Kleynhans
Jackie Kleynhans
AGAnne von Gottberg
Anne von Gottberg
MMMeredith L. McMorrow
Meredith L. McMorrow
FWFloidy Wafawanaka
Floidy Wafawanaka
South Africa was among the first countries to detect the SARS-CoV-2 Omicron variant. However, the size of its Omicron BA.1 and BA.2 subvariants (BA.1/2) wave remains poorly understood. We analyzed sequential serum samples collected through a prospective cohort study before, during, and after the Omicron BA.1/2 wave to infer infection rates and monitor changes in the immune histories of participants over time. We found that the Omicron BA.1/2 wave infected more than half of the cohort population, with reinfections and vaccine breakthroughs accounting for > 60% of all infections in both rural and urban sites. After the Omicron BA.1/2 wave, we found few (< 6%) remained naïve to SARS-CoV-2 and the population immunologic landscape is fragmented with diverse infection/immunization histories. Prior infection with the ancestral strain, Beta, and Delta variants provided 13%, 34%, and 51% protection against Omicron BA.1/2 infection, respectively. Hybrid immunity and repeated prior infections reduced the risks of Omicron BA.1/2 infection by 60% and 85% respectively. Our study sheds light on a rapidly shifting landscape of population immunity in the Omicron era and provides context for anticipating the long-term circulation of SARS-CoV-2 in populations no longer naïve to the virus.

24 August 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
KSKaiyuan Sun
Kaiyuan Sun
STStefano Tempia
Stefano Tempia
JKJackie Kleynhans
Jackie Kleynhans
AGAnne von Gottberg
Anne von Gottberg
MMMeredith L. McMorrow
Meredith L. McMorrow
CCCheryl Cohen
Cheryl Cohen
Understanding the build-up of immunity with successive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the epidemiological conditions that favor rapidly expanding epidemics will help facilitate future pandemic control. We analyzed high-resolution infection and serology data from two longitudinal household cohorts in South Africa to reveal high cumulative infection rates and durable cross-protective immunity conferred by prior infection in the pre-Omicron era. Building on the history of past exposures to different SARS-CoV-2 variants and vaccination in the cohort most representative of South Africa’s high urbanization rate, we used mathematical models to explore the fitness advantage of the Omicron variant and its epidemic trajectory. Modeling suggests that the Omicron wave likely infected a large fraction (44 to 81%) of the population, leaving a complex landscape of population immunity primed and boosted with antigenically distinct variants. We project that future SARS-CoV-2 resurgences are likely under a range of scenarios of viral characteristics, population contacts, and residual cross-protection.

8 July 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
VSVéronique Suttels
Véronique Suttels
JTJacques D Du Toit
Jacques D Du Toit
AFArnauld Fiogbé
Arnauld Fiogbé
AWAblo Prudence Wachinou
Ablo Prudence Wachinou
BGBrice Guendehou
Brice Guendehou
MHMary Anne Hartley
Mary Anne Hartley
Point-of-care ultrasound (POCUS) is an increasingly accessible skill, allowing for the decentralization of its use to nonspecialist healthcare workers to guide routine clinical decision-making. The advent of ultrasound-on-a-chip has transformed the technology into a portable mobile health device. Because of its high sensitivity to detect small consolidations, pleural effusions, and subpleural nodules, POCUS has recently been proposed as a sputum-free likely triage tool for tuberculosis (TB). To make an objective assessment of the potential and limitations of POCUS in routine TB management, we present a Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis based on a review of the relevant literature and focusing on Sub-Saharan Africa (SSA). We identified numerous strengths and opportunities of POCUS for TB management, e.g., accessible, affordable, easy to use and maintain, expedited diagnosis, extrapulmonary TB detection, safer pleural/pericardial puncture, use in children/pregnant women/people living with HIV, targeted screening of TB contacts, monitoring TB sequelae, and creating artificial intelligence decision support. Weaknesses and external threats such as operator dependency, lack of visualization of central lung pathology, poor specificity, lack of impact assessments and data from SSA must be taken into consideration to ensure that the potential of the technology can be fully realized in research as in practice.

3 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
ZCZeming Chen
Zeming Chen
ARAngelika Romanou
Angelika Romanou
AHAlejandro Hernández-Cano
Alejandro Hernández-Cano
BABadr Alkhamissi
Badr Alkhamissi
KMKyle Matoba
Kyle Matoba
ABAntoine Bosselut
Antoine Bosselut
Large language and multimodal models (LLMs and LMMs) will transform access to medical knowledge and clinical decision support. However, the current leading systems fall short of this promise, as they are either limited in scale, which restricts their capabilities, closed-source, which limits the extensions and scrutiny that can be applied to them, or not sufficiently adapted to clinical settings, which inhibits their practical use. In this work, we democratize large-scale medical AI systems by developing MEDITRON: a suite of open-source LLMs and LMMs with 7B and 70B parameters adapted to the medical domain. MEDITRON extends pretraining on a comprehensively curated medical corpus that includes biomedical literature and internationally recognized clinical practice guidelines. Evaluations using standard medical reasoning benchmarks show significant improvements over all current open-access models and several state-of-the-art commercial LLMs that are orders of magnitude larger, more expensive to host, and closed-source. Enhanced with visual processing capabilities, our MEDITRON-V model also outperforms all open-access models and much larger closed-source models on multimodal reasoning tasks for various biomedical imaging modalities. Beyond traditional benchmarks, we also create a novel and physician-driven adversarial question dataset grounded in real-world clinical settings, and a comprehensive 17-metric evaluation rubric to assess alignment and contextualization to real-world clinical practice. Applying this framework to MEDITRON-70B's responses, sixteen independent physicians found a high level of alignment across all metrics, including medical accuracy, safety, fairness, communication, and interpretation. The MEDITRON suite is a significant step forward in closing the technological gap between closed- and open-source medical foundation models. By releasing our methodologies, models, and real-world clinical practice benchmarks, we aim to drive the open-source development of more capable, representative, accessible, and transparent medical AI assistants.

1 August 2023 in Hypertension
Verified
Journal Article
Closed access
EFEnrico G. Ferro
Enrico G. Ferro
SAShafika Abrahams-Gessel
Shafika Abrahams-Gessel
DKDavid Kapaon
David Kapaon
BHBrian Houle
Brian Houle
JTJacques D Du Toit
Jacques D Du Toit
TGThomas A. Gaziano
Thomas A. Gaziano
BACKGROUND: Sub-Saharan Africa is undergoing an epidemiologic transition from infectious diseases to cardiovascular diseases. From 2014 to 2019, sociodemographic surveillance was performed in a large cohort in rural South Africa. METHODS: Disease prevalence and incidence were calculated using inverse probability weights. Poisson regression was used to identify disease predictors. The percentage of individuals with controlled (<140/90 mm Hg) versus uncontrolled hypertension was compared between 2014 and 2019. RESULTS: Compared with 2014 (n=5059), study participants in 2019 (n=4176) had similar rates of obesity (mean body mass index, 27.5±10.0 versus 27.0±6.5) but higher smoking (9.1% versus 11.5%) and diabetes (11.1% versus 13.9%). There was no significant increase in hypertension prevalence (58.4% versus 59.8%; age adjusted, 64.3% versus 63.3%), and there was a significant reduction in mean systolic blood pressure (138.0 versus 128.5 mm Hg; P <0.001). Among hypertensive individuals who reported medication use in 2014 and 2019 (n=796), the proportion with controlled hypertension on medication increased from 44.5% to 62.3%. Hypertension incidence was 6.2 per 100 person-years, and age was the only independent predictor. Among normotensive individuals in 2014 (n=2257), 15.2% developed hypertension by 2019, with the majority already controlled on medications by 2019. CONCLUSIONS: The hypertension prevalence and incidence are plateauing in this aging cohort. There was a statistically and clinically significant decline in mean blood pressure and a substantial increase in individuals with controlled hypertension on medication. The prevalence of cardiometabolic risk factors did not decrease over time, suggesting that the blood pressure decrease is likely due to increased medication access and adherence, promoted by local health systems.